.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The FLOW trial evaluated once-weekly semaglutide in adults with type 2 diabetes and chronic kidney disease. The study showed that semaglutide reduced the risk of a composite kidney outcome and cardiovascular death compared with placebo, adding important evidence for renal protection with a GLP-1 receptor agonist. The results are especially relevant to general physicians because diabetic kidney disease often evolves silently and coexists with cardiovascular disease. A modern nephroprotective strategy therefore requires systematic use of albuminuria and estimated GFR, blood-pressure control and selection of therapies that modify both renal and cardiovascular risk. Semaglutide is not a substitute for established renin–angiotensin system blockade or SGLT2 inhibition where indicated; instead, it adds another evidence-based option within a layered approach. The trial also illustrates why kidney outcomes are becoming increasingly important endpoints in diabetes drug development. For routine practice, the emphasis should remain on risk stratification, persistence with therapy and periodic reassessment of kidney function and albuminuria.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FLOW trial evaluated once-weekly semaglutide in adults with type 2 diabetes and chronic kidney disease. The study showed that semaglutide reduced the risk of a composite kidney outcome and cardiovascular death compared with placebo, adding important evidence for renal protection with a GLP-1 receptor agonist. The results are especially relevant to general physicians because diabetic kidney disease often evolves silently and coexists with cardiovascular disease. A modern nephroprotective strategy therefore requires systematic use of albuminuria and estimated GFR, blood-pressure control and selection of therapies that modify both renal and cardiovascular risk. Semaglutide is not a substitute for established renin–angiotensin system blockade or SGLT2 inhibition where indicated; instead, it adds another evidence-based option within a layered approach. The trial also illustrates why kidney outcomes are becoming increasingly important endpoints in diabetes drug development. For routine practice, the emphasis should remain on risk stratification, persistence with therapy and periodic reassessment of kidney function and albuminuria.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
